Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
- SanBio to Ax 22 Jobs in US, Focus on Work towards Japan Cell Therapy Launch
July 12, 2023
- RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
July 12, 2023
- JCR Grabs German OK for Launch of Global PI/II for MPS IIIA Drug
July 12, 2023
- Eisai’s Alzheimer’s Skipper to Retire after Full Leqembi Approval
July 12, 2023
- Astellas Bags Rights to 4DMT’s Gene Therapy Vector for Eye Diseases
July 12, 2023
- Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
- Japan Ethical Drug Sales Up 7.2% in May: Crecon
July 10, 2023
- Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
- Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
July 7, 2023
- Meiji/Zeria Grabs Thai Approval for Functional Dyspepsia Drug
July 7, 2023
- Astellas’ 1st-in-Class Gastric Cancer Med Bags Priority Review in US
July 7, 2023
- Opdivo Extends Streak of Best-Seller Title to 18 Months: Encise
July 7, 2023
- FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
- Taiho’s FGFR Inhibitor Lytgobi Grabs Conditional OK in Europe
July 6, 2023
- Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
- Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
- Shionogi Files Xofluza for Pediatric Indication in Taiwan
July 5, 2023
- Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan
July 5, 2023
- Nippon Shinyaku’s DMD Drug Gets Rare Pediatric Disease Tag in US
July 5, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…